Opus Genetics (IRD) Assets Average (2011 - 2026)
Opus Genetics (IRD) posted quarterly Assets Average of $58.5 million for Q1 2026, up 37.64% year-over-year from $42.5 million in Q1 2025, and up 35.51% quarter-over-quarter from $43.2 million in Q4 2025.
Opus Genetics (IRD) Assets Average (2011 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Assets Average for 16 consecutive years, with $58.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 37.64% year-over-year to $58.5 million; the TTM figure through Mar 2026 stood at $58.5 million (up 37.64% YoY), while the FY2025 annual figure was $43.6 million, down 4.08% from the prior year.
- Assets Average rose to $58.5 million in Q1 2026 per IRD's latest filing, from $43.2 million in the prior quarter.
- Across five years, Assets Average topped out at $58.5 million in Q1 2026 and bottomed at $16.2 million in Q3 2022.
- Historically, Assets Average has averaged $40.7 million across 5 years, with a median of $43.2 million in 2025.
- Annual changes were most pronounced in 2022 — Assets Average plunged 33.0% — and 2023, when it soared 200.79%.
- Opus Genetics' Assets Average stood at $31.8 million in 2022, then surged by 70.14% to $54.1 million in 2023, then fell by 28.56% to $38.6 million in 2024, then rose by 11.8% to $43.2 million in 2025, then surged by 35.51% to $58.5 million in 2026.
- Business Quant data shows IRD's Assets Average at $58.5 million in Q1 2026, $43.2 million in Q4 2025, and $37.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | 79.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 79.88 Mn |
| Mar 31, 2026 | 58.52 Mn |
| Dec 31, 2025 | 43.18 Mn |
| Sep 30, 2025 | 37.39 Mn |
| Jun 30, 2025 | 43.42 Mn |
| Mar 31, 2025 | 42.51 Mn |
| Dec 31, 2024 | 38.63 Mn |
| Sep 30, 2024 | 42.61 Mn |
| Jun 30, 2024 | 48.34 Mn |
| Mar 31, 2024 | 52.90 Mn |
| Dec 31, 2023 | 54.07 Mn |
| Sep 30, 2023 | 48.83 Mn |
| Jun 30, 2023 | 44.43 Mn |
| Mar 31, 2023 | 47.20 Mn |
| Dec 31, 2022 | 31.78 Mn |
| Sep 30, 2022 | 16.23 Mn |
| Jun 30, 2022 | 19.19 Mn |
| Mar 31, 2022 | 23.28 Mn |
| Dec 31, 2021 | 24.64 Mn |
| Sep 30, 2021 | 24.23 Mn |